Articles From: Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 to Sunesis Announces Amendment to Loan Agreement


2015/3/2
MENLO PARK, Calif.
Sign-up for Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 investment picks
2015/3/2
PCTEL, Inc. (NASDAQ:PCTI), a leader in P erformance C ritical Tel ecom solutions, announced its 2014 fourth quarter and annual results.
Sign-up for PCTEL Achieves $29.4 Million in Fourth Quarter Revenue investment picks
2015/3/2
Seventy Seven Energy Inc. (NYSE: SSE) today reported financial and operational results for the 2014 full year and fourth quarter.
Sign-up for Seventy Seven Energy Inc. Announces 2014 Full Year and Fourth Quarter Operational and Financial Results and the Date of its First Annual Meeting of Shareholders investment picks
2015/3/2
AT&T Works with Sany America to Manage Sany Heavy Equipment in North America DALLAS , March 2, 2015 /PRNewswire/ -- AT&T * is working with Sany America to monitor and manage its heavy equipment machinery in North America with telematics services.
Sign-up for AT&T Makes It Easier To Track And Manage Commercial Equipment investment picks
2015/3/2
PARSIPPANY, N.J., March 2, 2015 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (Nasdaq:CAR) , a leading global provider of vehicle rental services, announced today that it has agreed to acquire Maggiore Group, Italy's fourth-largest vehicle rental business.
Sign-up for Avis Budget Group Agrees to Acquire Maggiore Group investment picks
2015/3/2
CARLSBAD, Calif.
Sign-up for Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx investment picks
2015/3/2
The results from two positive bioavailability studies, previously reported by the Company, demonstrate the safety and tolerability of BEKINDA ™ and support the European marketing application submitted for BEKINDA ™ and the planned submission of a U.S. New Drug Application (NDA) for oncology support A European Marketing Authorization Application (MAA) for BEKINDA ™ for oncology support is currently under review by the UK MHRA, with feedback expected during H2/2015 Top-line results from the ongoing Phase III study with BEKINDA ™ (RHB-102) for acute gastroenteritis and gastritis (the GUARD study) are expected in Q4/2015 TEL-AVIV, Israel, March 2, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd.
Sign-up for Positive Bioavailability Studies of RedHill's BEKINDA(TM) to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting investment picks
2015/3/2
Endo Reports Fourth Quarter And Full Year 2014 Financial Results Canada NewsWire DUBLIN , March 2, 2015 /CNW/ -- Full year 2014 adjusted diluted EPS exceeds top end of guidance by $0.06 Total quarterly revenues of $800 million brings full year revenues to top end of guidance Fourth quarter reported $0.35 diluted (GAAP) loss per share and $1.16 adjusted diluted EPS Company announced separately today an agreement with Boston Scientific for the sale of American Medical Systems' (AMS) Men's Health and Prostate Health businesses as part of plan to fully divest the AMS business Company expects 2015 revenues, excluding AMS, to range from $2.90 billion to $3.00 billion Company expects 2015 reported diluted (GAAP) earnings per share, excluding AMS, to range from $2.73 to $2.93 Company expects 2015 adjusted diluted earnings per share, excluding AMS, to range from
Sign-up for Endo Reports Fourth Quarter And Full Year 2014 Financial Results investment picks
2015/3/2
Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific Canada NewsWire DUBLIN , March 2, 2015 /CNW/ -- Boston Scientific to acquire leading male urology medical device businesses for a total consideration of up to $1.65 billion , with $1.6 billion in upfront cash Endo also evaluating strategic alternatives for AMS' Women's Health business Divestiture furthers Endo's strategic transition into a global specialty pharmaceuticals business Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced it has entered into a definitive agreement with Boston Scientific (NYSE: BSX) , under which Boston Scientific will acquire Endo's American Medical Systems' (AMS) Men's and Prostate Health businesses for up to $1.65 billion , with $1.6 billion in cash payable at closing.
Sign-up for Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific investment picks
2015/3/2
DUBLIN , March 2, 2015 /PRNewswire/ -- Full year 2014 adjusted diluted EPS exceeds top end of guidance by $0.06 Total quarterly revenues of $800 million brings full year revenues to top end of guidance Fourth quarter reported $0.35 diluted (GAAP) loss per share and $1.16 adjusted diluted EPS Company announced separately today an agreement with Boston Scientific for the sale of American Medical Systems' (AMS) Men's Health and Prostate Health businesses as part of plan to fully divest the AMS business Company expects 2015 revenues, excluding AMS, to range from $2.90 billion to $3.00 billion Company expects 2015 reported diluted (GAAP) earnings per share, excluding AMS, to range from $2.73 to $2.93 Company expects 2015 adjusted diluted earnings per share, excluding AMS, to range from $4.35 to $4.55 Endo International plc (NASDAQ: ENDP) (TSX: ENL) today
Sign-up for Endo Reports Fourth Quarter And Full Year 2014 Financial Results investment picks
2015/3/2
DUBLIN , March 2, 2015 /PRNewswire/ -- Boston Scientific to acquire leading male urology medical device businesses for a total consideration of up to $1.65 billion , with $1.6 billion in upfront cash Endo also evaluating strategic alternatives for AMS' Women's Health business Divestiture furthers Endo's strategic transition into a global specialty pharmaceuticals business Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced it has entered into a definitive agreement with Boston Scientific (NYSE: BSX) , under which Boston Scientific will acquire Endo's American Medical Systems' (AMS) Men's and Prostate Health businesses for up to $1.65 billion , with $1.6 billion in cash payable at closing.
Sign-up for Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific investment picks
2015/3/2
EWING, N.J. , March 2, 2015 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) , a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the appointment of Jean-Pierre Bizzari , M.D. to its Board of Directors.
Sign-up for Celator® Pharmaceuticals Appoints Jean-Pierre Bizzari to Board of Directors investment picks
2015/3/2
PHILADELPHIA , March 2, 2015 /PRNewswire/ -- Adjusted EBITDA, including discretionary adjustments by the Board of Directors of the General Partner, was $87.1 million (1) for the fourth quarter 2014, an approximate 39% increase from the prior year quarter Distributable cash flow, including discretionary adjustments by the Board of Directors of the General Partner, was $47.1 million (1) for the fourth quarter 2014, an approximate 29% increase from the prior year quarter ARP updated its 2015 financial outlook, including full year distribution guidance of $1.30 per unit at an expected coverage range of 1.2x to 1.4x ARP will discuss fourth quarter and full year 2014 financial and operational results on a conference call at 9AM ET on Monday, March 2 nd Atlas Resource Partners, L.P. (NYSE: ARP ) (" ARP " or "the Company") has reported operating and financial results for the fourth quarter and full year
Sign-up for Atlas Resource Partners, L.P. Reports Operating And Financial Results For The Fourth Quarter And Full Year 2014 investment picks
2015/3/2
BioLineRx Ltd.
Sign-up for BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment investment picks
2015/3/2
LONG ISLAND, N.Y., March 2, 2015 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (Nasdaq:LOAN) announced today that it has entered into a Line of Credit Agreement with Webster Business Credit Corporation pursuant to which the lender has agreed to advance up to $14 million at an interest rate of either LIBOR plus 4.75% or Prime plus $3.25% against assignments of mortgages and other collateral.
Sign-up for Manhattan Bridge Capital, Inc. Establishes a Three-Year $14 Million Revolving Line of Credit investment picks
2015/3/2
Tessera Technologies, Inc. (NASDAQ:TSRA) ("Tessera" or the "Company") today announced that Tom Lacey, chief executive officer, and Robert Andersen, chief financial officer, will present at the 27 th Annual ROTH Conference at the Ritz-Carlton Laguna Niguel on Monday, March 9, 2015.
Sign-up for Tessera to Present at the 27th Annual ROTH Conference in Laguna Niguel on March 9 investment picks
2015/3/2
Teleflex Incorporated (NYSE: TFX) , a leading global provider of medical devices for critical care and surgery, has announced three new group purchasing agreements with Premier, Inc. The new agreements cover Teleflex’s Weck ® brand of Endomechanical (Ligation and Stapling) products, Deknatel ® brand of Cardiovascular Suture, and Weck Vista ® brand of Bladeless Laparoscopic Access Ports.
Sign-up for Teleflex Incorporated Signs New Agreements with Premier, Inc. for Endomechanical (Ligation and Stapling) Products, Suture and Trocars investment picks
2015/3/2
RANDOLPH, Mass.
Sign-up for Concerned Shareholders of Synacor Comment on Operating Results, Disappointing 2015 Guidance investment picks
2015/3/2
Weingarten Realty Investors (NYSE: WRI), a leading owner, manager and developer of shopping centers, announced today that it acquired Cambrian Park Plaza in San Jose, California.
Sign-up for Weingarten Realty Announces the Acquisition of Cambrian Park Plaza in San Jose, California investment picks
2015/3/2
Absolute Software Partners with YEZZ, a Worldwide Mobile Brand Canada NewsWire Absolute persistence technology to be embedded into device firmware; enabling security and data protection that starts at the factory VANCOUVER , March 2 , 2015 /CNW/ - Absolute® Software Corporation (TSX: ABT) , the industry standard for persistent endpoint security and management solutions for computers, laptops, tablets and smartphones, today announced a partnership with YEZZ, a leading worldwide mobile brand.
Sign-up for Absolute Software Partners with YEZZ, a Worldwide Mobile Brand investment picks
2015/3/2
Absolute persistence technology to be embedded into device firmware; enabling security and data protection that starts at the factory VANCOUVER , March 2 , 2015 /PRNewswire/ - Absolute® Software Corporation (TSX: ABT) , the industry standard for persistent endpoint security and management solutions for computers, laptops, tablets and smartphones, today announced a partnership with YEZZ, a leading worldwide mobile brand.
Sign-up for Absolute Software Partners with YEZZ, a Worldwide Mobile Brand investment picks
2015/3/2
Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the launch of a secondary public offering of its common stock.
Sign-up for Catalent, Inc. Announces Launch of Secondary Public Offering of Common Stock investment picks
2015/3/2
WAKE FOREST, N.C. , March 2, 2015 /PRNewswire/ -- PowerSecure International, Inc. (NYSE: POWR) will present at the 27 th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel, CA at 8:30 a.m. PT / 11:30 a.m. ET on Tuesday, March 10, 2015 .
Sign-up for PowerSecure To Present At The 27th Annual ROTH Conference investment picks
2015/3/2
SL Green Realty Corp (NYSE:SLG) today announced that Swatch, the multinational company active in the manufacture and sale of finished watches and jewelry, signed a 2,113-square-foot lease for a Times Square store on the ground floor of 1515 Broadway.
Sign-up for SL Green Signs Swatch for Balance of Retail Space at 1515 Broadway investment picks
2015/3/2
Garmin International Inc., a unit of Garmin Ltd.
Sign-up for Garmin® Announces Sponsorship of Professional Snowboarders and 2015 X-Games Gold Medalists Mark McMorris and Silje Norendal investment picks
2015/3/2
SANTA MONICA, Calif.
Sign-up for Macerich To Present At Citi 2015 Global Property CEO Conference investment picks
2015/3/2
Alkermes plc (NASDAQ: ALKS) today announced a new drug candidate, ALKS 7119, for the treatment of agitation in patients with Alzheimer’s disease, major depressive disorder (MDD) and other central nervous system (CNS) indications.
Sign-up for Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation, Depression and Other CNS Diseases investment picks
2015/3/2
The Alere q is a revolutionary new platform designed to enable point-of-care access to a suite of molecular assays WALTHAM, Mass.
Sign-up for Alere Receives IVD CE Mark for Alere™ q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care investment picks
2015/3/2
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2014.
Sign-up for Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results investment picks
2015/3/2
SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the signing of an amendment to its loan and security agreement (the "Loan Agreement") with Oxford Finance LLC, Silicon Valley Bank, and Horizon Technology Finance Corporation (collectively, "the Lenders"). The amendment, effective February 27, 2015, creates an interest-only period from March 1, 2015 through February 1, 2016 on the remainder of Sunesis' loan balance.
Sign-up for Sunesis Announces Amendment to Loan Agreement investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 to Sunesis Announces Amendment to Loan Agreement
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent